title: Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice.
abstract: Ganstigmine (CHF2819) is an acetylcholinesterase inhibitor that increases acetylcholine in rat hippocampus and ameliorates scopolamine-induced amnesia. In this article, we examined whether and how ganstigmine might prevent or rescue the neurodegenerative phenotype in AD11 antinerve growth factor (anti-NGF) mice, a transgenic model for Alzheimer's disease. The effects of ganstigmine were compared with those obtained after administration of donepezil. Results demonstrate that intraperitoneal and oral administration of ganstigmine and donepezil can reverse the cholinergic and behavioral deficit in AD11 mice but not the amyloid and phosphotau accumulation, uncovering different mechanisms leading to neurodegeneration in AD11 mice.
authors.affiliation: Lay Line Genomics S.p.A., Rome, Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Capsoni
authors.forename: Sabina
authors.initials: S
authors.lastname: Giannotta
authors.forename: Marco
authors.initials: M
authors.lastname: Stebel
authors.forename: Addys Ancheta
authors.initials: AA
authors.lastname: Garcia
authors.forename: Roberta
authors.initials: R
authors.lastname: De Rosa
authors.forename: Gino
authors.initials: G
authors.lastname: Villetti
authors.forename: Bruno Pietro
authors.initials: BP
authors.lastname: Imbimbo
authors.forename: Claudio
authors.initials: C
authors.lastname: Pietra
authors.forename: Antonino
authors.initials: A
authors.lastname: Cattaneo
mesh_terms: D000284:Administration, Oral; D000470:Alkaloids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D000818:Animals; D000906:Antibodies / Q000276:immunology; D001522:Behavior, Animal / Q000187:drug effects; D002219:Carbamates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D000077265:Donepezil; D007150:Immunohistochemistry; D007189:Indans / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D051379:Mice; D008822:Mice, Transgenic; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000473:pathology* / Q000517:prevention & control; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors* / Q000187:drug effects*; D010766:Phosphorylation / Q000187:drug effects; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D016875:tau Proteins / Q000378:metabolism
chemical_list: D000470:Alkaloids; D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D000906:Antibodies; D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D016875:tau Proteins; D000077265:Donepezil; D020932:Nerve Growth Factor; C447079:ganstigmine